We reasoned that the effect of pramlintide cotreatment to lower serum glucagon:insulin ratio could be used alongside lower doses of liraglutide to enhance protection from olanzapine-induced hyperglycemia and enable lower doses of drugs to be used. The gene discussed is GCG; the disease is Hyperglycemia.